Trials / Completed
CompletedNCT00072774
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Three Fixed Doses (100 Mg, 200 Mg, Or 400 Mg) Of DVS-233 SR In Adult Outpatients With Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 480 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DVS-233 SR |
Timeline
- Primary completion
- 2004-11-01
- Completion
- 2004-11-01
- First posted
- 2003-11-13
- Last updated
- 2009-08-19
Source: ClinicalTrials.gov record NCT00072774. Inclusion in this directory is not an endorsement.